What Is Downstream Purification in Biomanufacturing?

Downstream purification in biomanufacturing refers to the series of unit operations that separate a biologic drug substance from the cell culture in which it was produced, removing host cell proteins, DNA, aggregates, process chemicals, and potential viral contaminants to achieve the purity and quality required for patient administration. A standard monoclonal antibody downstream sequence includes primary harvest clarification by depth filtration, Protein A affinity capture, low-pH viral inactivation, one or two polishing chromatography steps (typically ion exchange), viral filtration, ultrafiltration and diafiltration for concentration and formulation, and final sterile filtration before fill and finish.

Why Does Downstream Purification Account for Most of the Cost of Biomanufacturing?

Downstream purification represents sixty to eighty percent of total biomanufacturing production costs primarily because of the capital intensity and operational complexity of chromatography and filtration systems at commercial scale. Protein A resin, which typically functions as the capture step for monoclonal antibodies, is among the most expensive materials used in biopharmaceutical manufacturing per gram of resin. Column hardware, buffer volumes, cycle times, and the analytical testing required to release each chromatographic fraction contribute additional costs. The multiple sequential unit operations required for viral safety, each requiring dedicated equipment, validation, and documentation, multiply these costs across the full downstream train.

What Are the Most Common Chromatography Modes Used in Downstream Biomanufacturing?

The six primary chromatography modes used in commercial biologics downstream processing are Protein A affinity chromatography (capture step for IgG-class antibodies and Fc-fusion proteins), cation exchange chromatography (polishing by charge-based selective binding), anion exchange chromatography (polishing in flow-through mode for viral, DNA, and endotoxin clearance), hydrophobic interaction chromatography (selectivity based on surface hydrophobicity, critical for ADC DAR separation), mixed-mode chromatography (combined ion exchange and hydrophobic interactions for challenging impurity removal), and size exclusion chromatography (primarily analytical for aggregate quantitation; preparative applications are limited by throughput at commercial scale).

What Is the Regulatory Requirement for Viral Clearance in Biopharmaceutical Manufacturing?

Viral clearance for biologics derived from mammalian cell culture is governed by ICH Q5A(R2), adopted in November 2023. The guidance requires that manufacturers demonstrate viral safety through a combination of virus testing of cell banks and in-process materials, and viral clearance validation showing that the production process is capable of removing and inactivating viruses across at least two independent, orthogonal mechanisms. Typical clearance mechanisms include low-pH viral inactivation for enveloped viruses and size-based nanofiltration for small non-enveloped parvovirus-sized model viruses. Each mechanism must demonstrate at least four log10 reduction in spiked virus studies conducted at small scale under conditions representative of the commercial process.

How Does Continuous Purification Differ from Batch Chromatography?

Batch chromatography loads a single column to capacity, washes it, elutes the product, and regenerates the column before loading again. The column is unproductive during the wash, elution, and regeneration phases. Continuous multi-column chromatography operates multiple columns in parallel in a coordinated sequence, so that while one column is in the productive loading phase, others are simultaneously in wash, elution, and regeneration. This arrangement maximizes the fraction of time each column spends in productive loading, increases resin utilization by thirty to fifty percent compared to batch operation, and reduces buffer consumption. ICH Q13 (2023) provides the regulatory framework for implementing continuous manufacturing, including continuous downstream bioprocessing.

What Is UF/DF and Why Is It Used at the End of the Purification Sequence?

Ultrafiltration and diafiltration (UF/DF) is a membrane-based concentration and buffer exchange process that typically represents the final formulation step in biologics downstream processing. Ultrafiltration concentrates the product by retaining molecules above the membrane molecular weight cutoff while allowing buffer components and small molecules to pass. Diafiltration exchanges the buffer surrounding the concentrated product by continuously adding formulation buffer while simultaneously filtering off the previous buffer, achieving buffer exchange efficiency proportional to the number of diafiltration volumes applied. UF/DF typically achieves twenty to fiftyfold concentration from the chromatography pool to the final formulated drug substance concentration.

How Has Upstream Process Intensification Affected Downstream Purification Design?

Upstream process intensification has increased the biological load presented to downstream purification systems in several ways. Higher viable cell densities in perfusion and intensified fed-batch processes produce harvests with greater turbidity, higher concentrations of host cell proteins from lysed cells, elevated DNA levels from apoptotic cells, and increased aggregate content. Depth filtration systems, Protein A column sizing, and early polishing step capacity must all be re-evaluated when intensified upstream processes are implemented. The consequence is that facilities designed for standard fed-batch titers of one to three grams per liter may require significant capacity modifications to handle intensified processes at five to ten grams per liter or above.

Articles

Mastering Downstream Purification: Advanced Chromatography and Filtration in Biomanufacturing

Upstream processing makes the product, but downstream processing makes the profit. Here is the chemistry and engineering you need to master it.

Updated

Written byTrevor J Henderson

A downstream purification laboratory showing a column chromatography skid with protein A resin column connected to a chromatography system, with a tangential flow filtration system visible in the background.

The downstream purification sequence for a monoclonal antibody typically involves five or more distinct unit operations, each targeting a specific class of process-related impurity. Optimizing yield and purity across the full sequence, while maintaining the regulatory evidence base for viral safety, is the core challenge of commercial biologics purification development.

Flow (2026)

Listen with Speechify

0:00

9:00

Downstream purification in biomanufacturing accounts for sixty to eighty percent of total production costs and determines whether a molecule with genuine therapeutic potential can be delivered at sufficient yield and purity for commercial distribution. From Protein A affinity capture through ion exchange polishing and viral filtration to final ultrafiltration and diafiltration, every step in the purification sequence is a chemistry and engineering problem that directly affects both product quality and the economics of the manufacturing program.

Key Takeaways

Downstream purification represents sixty to eighty percent of total biomanufacturing costs, making purification sequence design the primary lever for reducing the cost of goods of commercial biologics.

Process intensification in upstream bioreactors has fundamentally increased the downstream challenge: higher titers and more concentrated harvests mean more impurity mass, higher viscosity at harvest, and increased loading demands on every downstream unit operation.

A standard monoclonal antibody platform sequence, comprising Protein A capture, low-pH viral inactivation, ion exchange polishing, viral filtration, and UF/DF, has been validated across thousands of regulatory submissions. The challenge is adapting it for each specific molecule, impurity profile, and production scale.

Continuous purification using multi-column chromatography systems reduces resin utilization, buffer consumption, and processing time compared to equivalent batch purification at the same annual output target, and ICH Q13 (2023) provides the harmonized regulatory framework for implementing these approaches.

Viral clearance is non-negotiable and requires demonstration of at least two independent, orthogonal clearance mechanisms. ICH Q5A(R2), adopted November 2023, updated the regulatory framework for viral safety evaluation and introduced platform approaches that streamline clearance validation for well-characterized production processes.

This article serves as the technical anchor for Separation Science's downstream purification content cluster, covering the chromatography and filtration science underlying commercial biologics production. For the upstream bioprocessing context in which this purification science operates, see the ultimate guide to bioprocessing scale-up and Pharma 4.0.

The Economics of Downstream Purification

The downstream processing burden in biopharmaceutical manufacturing has intensified significantly over the past two decades as upstream titers have risen from approximately one gram per liter in the early 2000s to five to ten grams per liter in optimized commercial fed-batch processes today. Higher upstream productivity is, counter-intuitively, a downstream processing challenge: more product per liter of cell culture means more host cell protein, more DNA, more aggregates, more viral particles to be removed per production run, with the same or larger volume to be processed.

The economics of downstream processing are governed by three competing objectives: maximum product yield at each step, maximum impurity clearance at each step, and minimum buffer volume consumed in achieving the first two. These objectives are in genuine tension. Steps optimized for maximum binding capacity tend to operate under conditions that also bind some impurities, requiring subsequent polishing. Steps optimized for maximum purity tend to sacrifice some product yield at the boundaries of the elution gradient.

The purification sequence design challenge is to resolve this tension across five or more sequential unit operations, each with its own resin or membrane chemistry, operating conditions, and regulatory documentation requirements. The Merck application notebook on bioprocessing purification of biomolecules illustrates how this multi-step challenge plays out for monoclonal antibodies, bispecific antibodies, antibody fragments, and antibody-drug conjugates across resin chemistries from Protein A to mixed-mode to hydrophobic interaction.

How Has Process Intensification Changed the Downstream Challenge?

Process intensification strategies in upstream bioreactors, including N-1 perfusion seeding, high-density fed-batch, and continuous perfusion, have increased the biological load presented to downstream purification in ways that standard platform processes were not designed to handle. A perfusion bioreactor producing product at viable cell densities of fifty to one hundred fifty million cells per milliliter generates a harvest that is fundamentally different in impurity composition and concentration than a standard fed-batch harvest at ten to twenty million cells per milliliter.

High cell density harvests present increased turbidity and viscosity, higher concentrations of intracellular proteins released by lysed cells, elevated levels of DNA from late-stage apoptotic cells, and altered glycan profiles that affect resin binding behavior. Depth filtration systems sized for standard fed-batch clarification may be underspecified for perfusion harvests. Protein A chromatography columns sized for standard loading may require resizing to handle the higher product and impurity mass per cycle.

The downstream consequences of intensified upstream processes are now a primary design consideration for commercial facility planning. A 2022 review from the National Research Council Canada, Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies, provides a comprehensive survey of how single-use technologies, continuous bioprocessing, and advanced process analytical tools are reshaping the downstream challenge created by intensified upstream processes.

The Chromatography Toolbox for Biomanufacturing

Commercial biologics purification employs six primary chromatography interaction modes, each exploiting different molecular surface properties to achieve the selectivity required for its specific role in the purification sequence. Understanding the chemistry of each mode and the conditions under which competing impurities are retained or excluded from the stationary phase is fundamental to sequence design and optimization.

Mode	Interaction Basis	Primary Application in Biomanufacturing	Key Selectivity and Limitations
Protein A Affinity	Specific Protein A binding to antibody Fc region	Capture step for IgG-class monoclonal antibodies, Fc-fusion proteins, bispecific IgG formats	Exceptional selectivity; greater than 1,000-fold HCP clearance in a single step. Alkaline-sensitive resins require careful CIP conditions. Emerging alkaline-tolerant ligands extend resin lifetime. Not applicable to non-IgG-class molecules.
Cation Exchange (CEX)	Electrostatic attraction of positively charged protein surface to negatively charged resin	mAb polishing (bind-and-elute mode); charge variant analysis and resolution; HCP and aggregate clearance	pH and conductivity conditions critical for selectivity between product and closely related variants. Bind-and-elute mode concentrates product. Flow-through mode not applicable for anionic proteins.
Anion Exchange (AEX)	Electrostatic attraction of negatively charged impurities to positively charged resin	mAb polishing in flow-through mode; endotoxin removal; DNA clearance; viral clearance contribution	Most monoclonal antibodies flow through AEX at physiological pH, while viruses, DNA, endotoxins, and many HCPs are retained. Powerful as a polishing step when operated in flow-through mode. pH-sensitive for charge-variant selectivity.
Hydrophobic Interaction (HIC)	Interaction of hydrophobic surface patches with hydrophobic stationary phase, promoted by high salt concentrations	ADC polishing based on drug-to-antibody ratio (DAR); bispecific antibody purification; aggregate removal	Uniquely capable of resolving molecules that differ primarily in surface hydrophobicity rather than charge. High salt conditions required for binding may complicate buffer management. Critical for ADC DAR-based separation.
Mixed-Mode	Simultaneous or sequential ion exchange and hydrophobic interactions on a single resin	Challenging impurity removal where single-mode resins fail; aggregate clearance orthogonal to standard ion exchange; antibody fragment purification	Broader selectivity than single-mode resins; effective where impurities co-elute with product in pure IEX or HIC conditions. Buffer compatibility requires careful optimization. Useful for non-affinity platform purification of bispecific antibodies.
Size Exclusion (SEC)	Hydrodynamic volume-based separation through porous stationary phase with no binding interaction	Analytical aggregate quantitation (SEC-HPLC as QC release method); desalting; preparative aggregate removal for specialized applications	Gold standard for aggregate quantitation in QC release testing. Low throughput and dilution in preparative mode limit use at commercial scale to specialized applications. Excellent resolution of large aggregates from monomer.

Size exclusion chromatography occupies a distinct position in the downstream purification toolkit. As a preparative step, its low throughput limits commercial-scale use, but as an analytical method, SEC-HPLC is the gold standard for aggregate quantitation in drug substance release testing and a mandatory component of regulatory submissions for biologic drug products. For a practical guide to SEC column selection for biopharma analytical applications, including pore size selection, column dimensions, and maintenance strategies for mAb aggregate analysis, see the SEC column selection guide for biopharma analysts on Separation Science.

The Filtration Continuum: From Harvest to Final Sterility

Filtration in biopharmaceutical downstream processing is not a single operation but a continuum of membrane-based separations, each targeting a specific size range of impurities or achieving a specific process objective from harvest clarification through viral safety and final formulation.

Technology	Operating Principle	Primary Application	Scale-Up Considerations
Depth Filtration	Physical and charge-based retention in fibrous matrix; adsorptive as well as size-based	Primary harvest clarification of cell culture; bioburden reduction; turbidity and lipid removal before capture chromatography	Capacity and flux must be re-characterized for high-titer intensified harvests. Differential pressure across the filter bed is the primary scaling endpoint. Filter area scales proportionally with volume.
0.22 Micrometer Sterile Filtration	Absolute membrane retention by size; bioburden reduction to sterility	Bioburden reduction before column loading; final filtration before fill-finish; filtrate sterility assurance	Filter sizing based on loading volume and differential pressure limit. Protein aggregation can cause premature filter plugging at high concentration. Multi-filter configurations used for large-volume operations.
Tangential Flow Filtration (TFF)	Cross-flow across membrane surface prevents concentration polarization; product retained or passes depending on molecular weight cut-off	Concentration; buffer exchange (diafiltration); final formulation; continuous cell retention in perfusion bioreactors	Membrane area scales with processing volume and target flux. Hollow fiber and flat-sheet cassette formats serve different throughput and cleaning requirements. Transmembrane pressure management is critical for membrane integrity and product quality.
Viral Filtration (Parvovirus Removal)	Size-based retention of small non-enveloped viruses (nineteen to fifty nanometers) by asymmetric nanofiltration membranes	Mandatory viral clearance step for biologics derived from mammalian cell culture; provides at least four log10 reduction of parvovirus-sized model viruses	Flux is the primary scale-up challenge; high-titer loads and increased protein concentration after UF reduce available flux. Sizing must account for maximum product concentration and worst-case fouling scenario.
ATF Filtration	Alternating bidirectional flow through hollow fiber module using pressure-driven pumping; prevents membrane fouling through flow reversal	Cell retention in perfusion bioreactors; high-density continuous cell culture for upstream intensification	Hollow fiber pore size selection is critical for cell retention at high viable cell densities. Membrane fouling management through appropriate transmembrane pressure control. Integration with continuous downstream requires careful flow rate synchronization.

What Makes Viral Clearance Non-Negotiable?

Viral safety for biologic drugs derived from mammalian cell culture is a regulatory requirement that cannot be satisfied by process analytics or testing alone. The governing guidance, ICH Q5A(R2), adopted by the ICH Assembly in November 2023, establishes that confidence in viral safety derives not solely from direct testing for virus presence but from demonstrating that the purification process is capable of removing and inactivating viruses to a defined extent. Q5A(R2) updated and expanded the original 1999 guidance to address new product types, new analytical technologies including next-generation sequencing for virus detection, and platform approaches to clearance validation.

The regulatory framework requires demonstration of viral clearance through at least two independent, orthogonal mechanisms, typically: low-pH viral inactivation (exposing the protein A eluate to pH 3.4-3.8 for at least thirty minutes, inactivating enveloped viruses with greater than four log10 reduction), and size-based viral filtration (parvovirus-retentive nanofiltration membranes providing greater than four log10 clearance of small non-enveloped viruses). Ion exchange chromatography in appropriate binding or flow-through modes can contribute to viral clearance and may count as a third, complementary mechanism.

Viral clearance validation studies are performed at small scale using scaled-down column models spiked with relevant and model viruses. The reduction values demonstrated in these studies must account for the uncertainty in the scale-down model and provide adequate safety margin. Scale-down model qualification, demonstrating that the small-scale model accurately represents the commercial-scale process, is itself a regulatory expectation and a significant technical undertaking.

Continuous Purification and the Move Away from Batch Processing

The downstream bottleneck in high-titer biomanufacturing is increasingly Protein A chromatography capacity. A production bioreactor generating ten grams per liter of product creates a Protein A loading challenge that would require either very large columns, very frequent cycling, or both, in a standard batch operation. Multi-column continuous chromatography addresses this constraint by running multiple columns in parallel, loading the next column while the previous column is in washing, elution, and regeneration, and achieving far higher resin utilization and volumetric productivity than batch operation at the same annual output. ICH Q13 (Continuous Manufacturing of Drug Substances and Drug Products, 2023) provides the harmonized regulatory framework for continuous processing in pharmaceutical manufacturing, including continuous downstream bioprocessing, and explicitly addresses the control strategy considerations required to demonstrate process understanding in connected, continuous unit operations.

The principal continuous chromatography platforms include periodic counter-current (PCC) multi-column systems, which load product in a counter-current arrangement across two to four columns to maximize resin utilization, and simulated moving bed (SMB) systems, which approximate true counter-current movement through sequential column switching. Both approaches offer resin utilization improvements of thirty to fifty percent compared to batch operation and can be integrated with continuous upstream processes including perfusion bioreactors to create a fully continuous manufacturing train.

Buffer consumption, one of the highest operational costs in downstream processing, is also substantially reduced in continuous multi-column chromatography. By eliminating the wash and equilibration buffer volumes required to prepare a single column for each batch, and by reusing column equilibration buffer in counter-current loading schemes, multi-column systems achieve significant buffer savings. These savings propagate downstream, reducing the scale of buffer management infrastructure required and the operational burden of buffer preparation.

For industry developments in continuous multi-column chromatography platform design, including emerging multi-column systems that support both mAb and viral vector purification workflows, see Separation Science's coverage of continuous chromatography advancing in partnership between industry and academia. A 2025 study from WuXi Biologics published in the Journal of Biomolecular Methods demonstrated that multi-column continuous CEX chromatography improved the robustness of charge variant reduction in mAb polishing steps while maintaining step yield, confirming that MCC offers quality advantages beyond throughput and buffer savings.

How Do Downstream Decisions Affect Product Quality?

Product quality attributes for biologic drugs, including aggregate content, charge variant distribution, glycan profile, host cell protein (HCP) content, and DNA levels, are established by the combination of the cell culture process and the downstream purification sequence. Regulators expect these attributes to be consistently controlled to specifications that have been demonstrated to be safe and effective, and changes to the downstream process that affect critical quality attributes require regulatory notification and, in many cases, comparability studies.

Aggregate clearance is particularly sequence-sensitive. Protein A chromatography typically removes large aggregates effectively in the wash step, but smaller soluble aggregates may co-elute with the monomer. CEX chromatography provides additional aggregate resolution through charge-based differential binding under optimized pH and conductivity conditions. The aggregate specification in the drug substance release test (typically measured by SEC-HPLC) must be met with adequate safety margin, accounting for potential aggregate formation during storage and shipping.

HCP clearance is a particularly challenging quality objective because human cell proteins are structurally diverse, present at a wide range of concentrations in the cell culture harvest, and cannot be individually characterized by routine release testing. Platform HCP ELISA assays measure total HCP by immunoreactivity but may have coverage gaps for low-abundance proteins. The downstream purification sequence must be designed to achieve HCP clearance to levels that have been demonstrated safe, typically ten parts per million or below, across multiple orthogonal chromatography modes with different selectivities for different protein classes.

The Hidden Cost: Buffer Management in Large-Scale Purification

Buffer consumption in commercial-scale downstream processing is substantial and underappreciated as a cost driver. A commercial monoclonal antibody process operating a standard multi-step platform sequence may consume fifty to one hundred times the final drug substance volume in buffer, primarily for column equilibration, washing, and elution across the chromatographic sequence, and for the diafiltration cycles in the UF/DF step. Managing these volumes requires significant infrastructure for buffer preparation, holding, and transfer.

In-line buffer dilution, the practice of preparing concentrated buffer stocks and diluting them on-demand immediately before use rather than preparing and storing large-volume ready-to-use buffers, has emerged as the primary strategy for reducing buffer infrastructure requirements. By reducing the volume of liquid that must be stored and managed as a ready-to-use buffer, in-line dilution can eliminate entire holding tank installations from facility designs and reduce the footprint of the buffer preparation area by thirty to fifty percent.

This article was produced under Separation Science's AI Editorial Guidelines.

Frequently Asked Questions (FAQs)

What Is Downstream Purification in Biomanufacturing?
Downstream purification in biomanufacturing refers to the series of unit operations that separate a biologic drug substance from the cell culture in which it was produced, removing host cell proteins, DNA, aggregates, process chemicals, and potential viral contaminants to achieve the purity and quality required for patient administration. A standard monoclonal antibody downstream sequence includes primary harvest clarification by depth filtration, Protein A affinity capture, low-pH viral inactivation, one or two polishing chromatography steps (typically ion exchange), viral filtration, ultrafiltration and diafiltration for concentration and formulation, and final sterile filtration before fill and finish.
Why Does Downstream Purification Account for Most of the Cost of Biomanufacturing?
Downstream purification represents sixty to eighty percent of total biomanufacturing production costs primarily because of the capital intensity and operational complexity of chromatography and filtration systems at commercial scale. Protein A resin, which typically functions as the capture step for monoclonal antibodies, is among the most expensive materials used in biopharmaceutical manufacturing per gram of resin. Column hardware, buffer volumes, cycle times, and the analytical testing required to release each chromatographic fraction contribute additional costs. The multiple sequential unit operations required for viral safety, each requiring dedicated equipment, validation, and documentation, multiply these costs across the full downstream train.
What Are the Most Common Chromatography Modes Used in Downstream Biomanufacturing?
The six primary chromatography modes used in commercial biologics downstream processing are Protein A affinity chromatography (capture step for IgG-class antibodies and Fc-fusion proteins), cation exchange chromatography (polishing by charge-based selective binding), anion exchange chromatography (polishing in flow-through mode for viral, DNA, and endotoxin clearance), hydrophobic interaction chromatography (selectivity based on surface hydrophobicity, critical for ADC DAR separation), mixed-mode chromatography (combined ion exchange and hydrophobic interactions for challenging impurity removal), and size exclusion chromatography (primarily analytical for aggregate quantitation; preparative applications are limited by throughput at commercial scale).
What Is the Regulatory Requirement for Viral Clearance in Biopharmaceutical Manufacturing?
Viral clearance for biologics derived from mammalian cell culture is governed by ICH Q5A(R2), adopted in November 2023. The guidance requires that manufacturers demonstrate viral safety through a combination of virus testing of cell banks and in-process materials, and viral clearance validation showing that the production process is capable of removing and inactivating viruses across at least two independent, orthogonal mechanisms. Typical clearance mechanisms include low-pH viral inactivation for enveloped viruses and size-based nanofiltration for small non-enveloped parvovirus-sized model viruses. Each mechanism must demonstrate at least four log10 reduction in spiked virus studies conducted at small scale under conditions representative of the commercial process.
How Does Continuous Purification Differ from Batch Chromatography?
Batch chromatography loads a single column to capacity, washes it, elutes the product, and regenerates the column before loading again. The column is unproductive during the wash, elution, and regeneration phases. Continuous multi-column chromatography operates multiple columns in parallel in a coordinated sequence, so that while one column is in the productive loading phase, others are simultaneously in wash, elution, and regeneration. This arrangement maximizes the fraction of time each column spends in productive loading, increases resin utilization by thirty to fifty percent compared to batch operation, and reduces buffer consumption. ICH Q13 (2023) provides the regulatory framework for implementing continuous manufacturing, including continuous downstream bioprocessing.
What Is UF/DF and Why Is It Used at the End of the Purification Sequence?
Ultrafiltration and diafiltration (UF/DF) is a membrane-based concentration and buffer exchange process that typically represents the final formulation step in biologics downstream processing. Ultrafiltration concentrates the product by retaining molecules above the membrane molecular weight cutoff while allowing buffer components and small molecules to pass. Diafiltration exchanges the buffer surrounding the concentrated product by continuously adding formulation buffer while simultaneously filtering off the previous buffer, achieving buffer exchange efficiency proportional to the number of diafiltration volumes applied. UF/DF typically achieves twenty to fiftyfold concentration from the chromatography pool to the final formulated drug substance concentration.
How Has Upstream Process Intensification Affected Downstream Purification Design?
Upstream process intensification has increased the biological load presented to downstream purification systems in several ways. Higher viable cell densities in perfusion and intensified fed-batch processes produce harvests with greater turbidity, higher concentrations of host cell proteins from lysed cells, elevated DNA levels from apoptotic cells, and increased aggregate content. Depth filtration systems, Protein A column sizing, and early polishing step capacity must all be re-evaluated when intensified upstream processes are implemented. The consequence is that facilities designed for standard fed-batch titers of one to three grams per liter may require significant capacity modifications to handle intensified processes at five to ten grams per liter or above.

Add Separation Science as a preferred Google source to see more of our trusted coverage

Meet the Author(s):

Trevor J Henderson
Trevor Henderson, PhD, is a veteran Content Innovation Director and scientific strategist at LabX Media Group. With a career spanning three decades, Trevor is a recognized expert in scientific writing, creative content creation, and technical editing.
His academic pedigree in human biology, physical anthropology, and community health provides him with a rigorous analytical framework, which he applies to developing industry-leading content for scientists and lab technicians. Since 2013, Trevor has led content innovation initiatives that drive engagement within the laboratory technology sector.
View Full Profile

Here are some related topics that may interest you:

Loading Next Article...